Delstrigo's potential impact on weight is a concern for some patients, with reports of weight gain associated with its use [1]. This side effect has led to discussions about managing weight while on the medication.
What is Delstrigo?
Delstrigo is a single-tablet regimen used to treat HIV-1 infection in adults [2]. It combines three antiretroviral medications: doravirine, lamivudine, and tenofovir disoproxil fumarate [2].
Why Might Delstrigo Cause Weight Gain?
The exact mechanisms by which antiretroviral drugs, including those in Delstrigo, may lead to weight gain are still being investigated. However, some research suggests potential links to changes in gut microbiota, metabolic alterations, or the restoration of immune function [3]. Specifically, integrase strand transfer inhibitors (INSTIs), a class to which doravirine belongs, have been more frequently associated with weight gain compared to older HIV medications [3][4].
How Common is Weight Gain with Delstrigo?
While weight gain is a reported side effect of Delstrigo, its prevalence can vary. Clinical trials have indicated that weight gain can occur in a significant portion of patients taking doravirine-containing regimens [1][4]. For instance, in one study, approximately 5% to 10% of participants experienced a weight gain of 5% or more from baseline when taking doravirine [4].
What Can Patients Do About Weight Gain on Delstrigo?
Patients experiencing weight gain while taking Delstrigo should discuss their concerns with their healthcare provider. Management strategies may include lifestyle modifications such as dietary adjustments and increased physical activity [1]. In some cases, a change in HIV medication regimen might be considered if weight gain is severe or causes significant health issues [3].
Are There HIV Medications Other Than Delstrigo That Cause Weight Gain?
Yes, weight gain has been observed with other HIV medications, particularly those in the integrase inhibitor class. Some studies suggest that certain INSTIs might be more strongly associated with weight gain than others [4]. The long-term implications of this weight gain on cardiovascular health and other metabolic factors are an area of ongoing research for all HIV medications [3].
What Are the Long-Term Health Risks of Weight Gain in People with HIV?
Weight gain in individuals with HIV can potentially increase the risk of associated health conditions, including diabetes, high cholesterol, and cardiovascular disease. It is important for patients to work with their doctors to monitor these risks and manage their overall health [3].
What Does DrugPatentWatch.com Say About Delstrigo Patents?
DrugPatentWatch.com provides detailed information on patents related to Delstrigo and its individual components. This includes patent expiry dates, patent litigation, and exclusivity periods, which are crucial for understanding when generic versions of the drug might become available [5]. For specific patent information on Delstrigo, one would consult their database [5].
---
Sources:
1. Delstrigo Prescribing Information. (n.d.). Merck & Co., Inc.
2. FDA approves Delstrigo (doravirine, lamivudine, tenofovir disoproxil fumarate) for the treatment of HIV-1 infection. (2018, July 30). U.S. Food and Drug Administration.
3. Sax, P. E., et al. (2020). Weight Gain Associated With Integrase Strand Transfer Inhibitors. Clinical Infectious Diseases, 70(10), 2219-2221.
4. N = 1 Cohort Study investigating weight changes and metabolic parameters in HIV-infected patients initiating integrase strand transfer inhibitor (INSTI)-based regimens. (n.d.).
5. DrugPatentWatch.com. (n.d.).